Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.37 - $0.96 $1,443 - $3,744
-3,900 Reduced 72.22%
1,500 $1,000
Q2 2024

Aug 14, 2024

BUY
$0.66 - $1.05 $3,432 - $5,460
5,200 Added 2600.0%
5,400 $4,000
Q1 2024

May 15, 2024

SELL
$0.95 - $1.5 $285 - $450
-300 Reduced 60.0%
200 $0
Q3 2023

Nov 14, 2023

SELL
$1.63 - $3.94 $488 - $1,182
-300 Reduced 37.5%
500 $0
Q2 2023

Aug 14, 2023

BUY
$2.99 - $4.15 $2,392 - $3,320
800 New
800 $2,000

Others Institutions Holding SLGL

About Sol-Gel Technologies Ltd.


  • Ticker SLGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,129,500
  • Market Cap $12.5M
  • Description
  • Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has compl...
More about SLGL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.